A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus

Non-Small Cell Lung Cancer Clinical Trial

— LUCENCE  

Official title:

A Multinational, Non-Interventional, Prospective Study of Nivolumab (BMS-936558) in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus - The 'Lucence' Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05034926
• Other study ID #: CA209-7U9
• Status: Active, not recruiting
• Start date: October 7, 2020
• Est. completion date: September 15, 2025

Study information

• Verified date: February 2023
• Source: Bristol-Myers Squibb
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this observational study is to estimate the overall survival (OS) rates in the overall study population treated with nivolumab in the second and third line setting in real world clinical practice in Greece and Cyprus. The study is descriptive in nature and is not planned to reject or affirm any formal statistical hypothesis.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 350
• Est. completion date: September 15, 2025
• Est. primary completion date: September 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Male or female adult Greek-speaking patients, of any race (residing in Greece or Cyprus), aged at least 18 years at time of initiation of nivolumab treatment.
• Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic (stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) with Squamous Cell Carcinoma (SCC) or Non-Squamous Cell Carcinoma (NSCC) histological subtype
• Initiated on second or third line treatment with nivolumab as monotherapy after prior chemotherapy as per the product's Summary of Product Characteristics (SmPC) prior to informed consent obtainment, and for whom therapy is ongoing and no more than one infusion has been administered from treatment initiation to obtaining the signed informed consent
• Decision to prescribe nivolumab treatment has been taken prior to their enrollment in the study and is clearly separated from the physician's decision to include the patient in the current study
• Provided signed informed consent for participating in the study and for collecting and analyzing medical data pertinent to the objectives of this study

Exclusion Criteria:

• Current primary diagnosis of a cancer other than NSCLC that requires systemic or other treatment
• Previously treated with nivolumab or other non-chemotherapy agents, with the exception of immune checkpoint inhibitors (anti-PD-1(Programmed cell death-1)/anti-PD-L1 (Programmed death-ligand 1) agent, other than nivolumab) administered in combination with chemotherapy
• Currently receiving or are planned to receive treatment with any investigational drug/device/intervention or who have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) prior to nivolumab therapy initiation

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-Small Cell Lung Cancer

Locations

Country	Name	City	State
Greece	Local Institution - 0001	Athens

Sponsors (1)

Lead Sponsor	Collaborator
Bristol-Myers Squibb

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of participants surviving at the landmark timepoint of 12 months after the initiation of nivolumab treatment, in the overall study population		Up to 12 months
Primary	Proportion of participants surviving at the landmark timepoint of 24 months after the initiation of nivolumab treatment, in the overall study population		Up to 24 months
Primary	Proportion of participants surviving at the landmark timepoint of 36 months after the initiation of nivolumab treatment, in the overall study population		Up to 36 months
Secondary	Proportion of participants surviving at the landmark timepoint 12 months after the initiation of nivolumab treatment, among the Squamous Cell Carcinoma (SCC) subpopulation		Up to 12 months
Secondary	Proportion of participants surviving at the landmark timepoint 24 months after the initiation of nivolumab treatment, among the SCC subpopulation		Up to 24 months
Secondary	Proportion of participants surviving at the landmark timepoint 36 months after the initiation of nivolumab treatment, among the SCC subpopulation		Up to 36 months
Secondary	Proportion of participants surviving at the landmark timepoint 12 months after the initiation of nivolumab treatment, among the Non-Squamous Cell Carcinoma (NSCC) subpopulation		Up to 12 months
Secondary	Proportion of participants surviving at the landmark timepoint 24 months after the initiation of nivolumab treatment, among the NSCC subpopulation		Up to 24 months
Secondary	Proportion of participants surviving at the landmark timepoint 36 months after the initiation of nivolumab treatment, among the NSCC subpopulation		Up to 36 months
Secondary	Proportion of participants surviving at the landmark timepoint 12 months after the initiation of nivolumab treatment per line of nivolumab treatment		Up to 12 months
Secondary	Proportion of participants surviving at the landmark timepoint 24 months after the initiation of nivolumab treatment per line of nivolumab treatment		Up to 24 months
Secondary	Proportion of participants surviving at the landmark timepoint 36 months after the initiation of nivolumab treatment per line of nivolumab treatment		Up to 36 months
Secondary	Proportion of participants who have not progressed or died from any cause at the landmark timepoint 12 months after the initiation of nivolumab treatment		Up to 12 months
Secondary	Proportion of participants who have not progressed or died from any cause at the landmark timepoint 24 months after the initiation of nivolumab treatment		Up to 24 months
Secondary	Proportion of participants who have not progressed or died from any cause at the landmark timepoint 36 months after the initiation of nivolumab treatment		Up to 36 months
Secondary	Proportion of participants with an investigator-assessed best overall response (BOR) of either a confirmed complete response (CR) or confirmed PR (ORR rate) at the landmark timepoint of 12 months after the initiation of nivolumab treatment	This refers to the overall study population, the SCC and NSCC subpopulations, and the subpopulations per line of nivolumab treatment.	Up to 12 months
Secondary	Proportion of participants with an investigator-assessed BOR of confirmed CR or PR or stable disease (SD) (DCR rate), at the landmark timepoint of 12 months after the initiation of nivolumab treatment	This refers to the overall study population, the SCC and NSCC subpopulations, and the subpopulations per line of nivolumab treatment.	Up to 12 months
Secondary	Time from start of nivolumab treatment to the first documented investigator-assessed response (CR or PR) (i.e., TTR), among participants who achieved at least PR	This refers to the overall study population, the SCC and NSCC subpopulations, and the subpopulations per line of nivolumab treatment.	Up to approximately 59 months
Secondary	Time from start of nivolumab treatment to best response (e.g., if a participant had both PR and CR, time to CR), among participants who achieved at least PR	This refers to the overall study population, the SCC and NSCC subpopulations, and the subpopulations per line of nivolumab.	Up to approximately 59 months
Secondary	Kaplan-Meier estimated median time from first documented response (CR or PR) to the date of first documented progression or death (due to any cause in the absence of progression), among participants who achieved at least PR (i.e., DoR)	This refers to the overall study population, the SCC and NSCC subpopulations, and the subpopulations per line of nivolumab.	Up to approximately 59 months
Secondary	Kaplan-Meier estimated median time from best response (e.g., if a patient had both PR and CR, time from CR) to the date of first documented progression or death (due to any cause in the absence of progression), among patients who achieved at least PR	This refers to the overall study population, the SCC and NSCC subpopulations, and the subpopulations per line of nivolumab.	Up to approximately 59 months
Secondary	Frequencies of baseline participant and disease characteristics of interest	This refers to the overall study population and the SCC and NSCC subpopulation.	Up to approximately 59 months
Secondary	Distribution of associations of baseline participant and disease characteristics with survival at 36 months post-treatment initiation		Up to 36 months
Secondary	Distribution of the number of nivolumab doses administered	This refers to the overall study population, the SCC and NSCC subpopulations, and the subpopulations per line of nivolumab treatment.	Up to approximately 59 months
Secondary	Distribution of the rate of dose modifications (including dose delays/withholdings)	This refers to the overall study population, the SCC and NSCC subpopulations, and the subpopulations per line of nivolumab treatment.	Up to approximately 59 months
Secondary	Distribution of the rate of permanent treatment discontinuation	This refers to the overall study population, the SCC and NSCC subpopulations, and the subpopulations per line of nivolumab treatment.	Up to approximately 59 months
Secondary	Distribution of the frequencies of reasons for dose modifications/discontinuations	This refers to the overall study population, the SCC and NSCC subpopulations, and the subpopulations per line of nivolumab treatment.	Up to approximately 59 months
Secondary	Distribution of the types and frequencies of next treatment planned to be administered for NSCLC after nivolumab discontinuation	This refers to the overall study population, the SCC and NSCC subpopulations, and the subpopulations per line of nivolumab treatment.	Up to approximately 59 months
Secondary	Kaplan-Meier estimated time from nivolumab treatment initiation until discontinuation due to any reason	This refers to the overall study population, the SCC and NSCC subpopulations, and the subpopulations per line of nivolumab treatment.	Up to approximately 59 months
Secondary	Distribution of exposure-adjusted incidence rate (EAIR), severity (grade), and management of the specified types of treatment-related AEs in the overall study population		Up to approximately 59 months
Secondary	Time to onset of high-grade (Grade 3 or higher) immune-related adverse events (irAEs) per AE category		Up to approximately 59 months
Secondary	Time to resolution of high-grade (Grade 3 or higher) irAEs per AE category		Up to approximately 59 months
Secondary	Incidence of adverse events leading to nivolumab treatment permanent discontinuation, in the overall study population		Up to approximately 59 months
Secondary	Distribution of type of adverse events leading to nivolumab treatment permanent discontinuation, in the overall study population		Up to approximately 59 months
Secondary	Change in the total LCSS score in the overall study population		Up to approximately 59 months
Secondary	Change in the total ASBI score throughout the study observation period examined using longitudinal analysis		Up to approximately 59 months
Secondary	Change in the total Average Symptom Burden Index (ASBI) score, in the overall study population	In addition, change in the total ASBI score throughout the study observation period will be examined using longitudinal analysis	Up to approximately 59 months
Secondary	Change in the individual domain scores from baseline to each post-baseline predefined timepoint in the overall study population		Up to approximately 59 months
Secondary	Symptom improvement rate, at the post-baseline predefined timepoints, using the Lung Cancer Symptom Scale (LCSS) Average Symptom Burden Index (ASBI), in the overall study population		Up to approximately 59 months
Secondary	Change in the EuroQol (EQ-5D) utility index score, from baseline at the post-baseline predefined timepoints, in the overall study population		Up to approximately 59 months
Secondary	Change in the EuroQol Visual Analogue Scale (EQ-VAS) score, from baseline at the post-baseline predefined timepoints, in the overall study population		Up to approximately 59 months
Secondary	Change in the proportion of participants in the five-level version of the EuroQol five-dimensional questionnaire (EQ-5D-5L) dimension levels (no problems, with problems) from baseline at the post-baseline predefined timepoints	in the overall study population	Up to approximately 59 months
Secondary	Distribution of Person-time incidence rate (per 100 participant-weeks) of inpatient hospitalizations for the management of treatment-related AEs, during the entire study observation period, in the overall study population		Up to approximately 59 months
Secondary	Distribution of Emergency room attendances for the management of treatment-related AEs, during the entire study observation period, in the overall study population		Up to approximately 59 months
Secondary	Distribution of Hospital outpatient visits for the management of treatment-related AEs, during the entire study observation period, in the overall study population		Up to approximately 59 months
Secondary	Distribution of Visits at office-based physicians for the management of treatment-related AEs, during the entire study observation period, in the overall study population		Up to approximately 59 months
Secondary	Distribution of Home visits by physicians, during the entire study observation period, in the overall study population		Up to approximately 59 months
Secondary	Distribution of Length of hospital stay, during the entire study observation period, in the overall study population		Up to approximately 59 months
Secondary	Distribution of Types and frequencies of medical procedures/interventions/diagnostic testing utilization, during the entire study observation period, in the overall study population		Up to approximately 59 months
Secondary	Distribution of Prescribed medications for the management of treatment-related AEs, during the entire study observation period, in the overall study population		Up to approximately 59 months

External Links

•   BMS Clinical Trial Information
•   FDA Safety Alerts and Recalls